[Skip to Content]
[Skip to Content Landing]
October 18, 2006

Poorer Outcomes for Recipients of Heart Allografts From HCV-Positive DonorsOpening the Silos

Author Affiliations

Author Affiliations: Department of Medicine, Harvard Medical School (Drs Qamar and Rubin), and Division of Gastroenterology, Hepatology, and Endoscopy (Dr Qamar) and Division of Infectious Diseases (Dr Rubin), Brigham and Women’s Hospital, Boston, Mass.

JAMA. 2006;296(15):1900-1901. doi:10.1001/jama.296.15.1900

Over the past 30 years, organ transplantation has evolved from an interesting experiment in human immunobiology to the most practical means of rehabilitating patients with end-stage dysfunction.1 At the same time, the requirement for chronic antirejection therapy, the presence of chronic or relapsing viral infection, and environmental exposures to a variety of opportunistic pathogens, have created a pathophysiological state and set of vulnerabilities rarely seen before.2,3 It has been estimated that 75% or more of organ transplant patients will have evidence of microbial replication and invasion in the first year posttransplant.46 Several principles have emerged from this experience.

First Page Preview View Large
First page PDF preview
First page PDF preview